Published in Glia on January 15, 2003
Mammalian nicotinic acetylcholine receptors: from structure to function. Physiol Rev (2009) 5.64
A DNA methylation fingerprint of 1628 human samples. Genome Res (2011) 2.16
Neuroinflammatory processes in Alzheimer's disease. J Neural Transm (Vienna) (2010) 1.73
Cholinergic system during the progression of Alzheimer's disease: therapeutic implications. Expert Rev Neurother (2008) 1.63
Deletion of the alpha 7 nicotinic acetylcholine receptor gene improves cognitive deficits and synaptic pathology in a mouse model of Alzheimer's disease. J Neurosci (2009) 1.42
Interactions between beta-amyloid and central cholinergic neurons: implications for Alzheimer's disease. J Psychiatry Neurosci (2004) 1.30
Nicotinic ACh receptors as therapeutic targets in CNS disorders. Trends Pharmacol Sci (2015) 1.26
Nicotinic acetylcholine receptor signalling: roles in Alzheimer's disease and amyloid neuroprotection. Pharmacol Rev (2009) 1.24
Mild cognitive impairment: pathology and mechanisms. Acta Neuropathol (2011) 1.20
The nicotinic acetylcholine receptor CHRNA5/A3/B4 gene cluster: dual role in nicotine addiction and lung cancer. Prog Neurobiol (2010) 1.09
Loss of alpha7 nicotinic receptors enhances beta-amyloid oligomer accumulation, exacerbating early-stage cognitive decline and septohippocampal pathology in a mouse model of Alzheimer's disease. J Neurosci (2010) 1.04
Functional α7 nicotinic ACh receptors on astrocytes in rat hippocampal CA1 slices. J Mol Neurosci (2012) 0.98
Alpha7 nicotinic acetylcholine receptor: a link between inflammation and neurodegeneration. Neurosci Biobehav Rev (2007) 0.95
Characterization of a multiple ligand-gated ion channel cellular membrane affinity chromatography column and identification of endogenously expressed receptors in astrocytoma cell lines. Anal Chem (2008) 0.90
Positive and negative effects of alcohol and nicotine and their interactions: a mechanistic review. Neurotox Res (2011) 0.88
Picomolar amyloid-β peptides enhance spontaneous astrocyte calcium transients. J Alzheimers Dis (2014) 0.87
Cholinergic and glutamatergic alterations beginning at the early stages of Alzheimer disease: participation of the phospholipase A2 enzyme. Psychopharmacology (Berl) (2008) 0.86
Cortical alpha7 nicotinic acetylcholine receptor and beta-amyloid levels in early Alzheimer disease. Arch Neurol (2009) 0.86
³H-deprenyl and ³H-PIB autoradiography show different laminar distributions of astroglia and fibrillar β-amyloid in Alzheimer brain. J Neuroinflammation (2013) 0.83
Temporally- and spatially-regulated transcriptional activity of the nicotinic acetylcholine receptor beta4 subunit gene promoter. Neuroscience (2010) 0.82
Research tool: Validation of floxed α7 nicotinic acetylcholine receptor conditional knockout mice using in vitro and in vivo approaches. J Physiol (2014) 0.80
Activation of α7-containing nicotinic receptors on astrocytes triggers AMPA receptor recruitment to glutamatergic synapses. J Neurochem (2013) 0.80
A transcriptional regulatory element critical for CHRNB4 promoter activity in vivo. Neuroscience (2010) 0.79
Regional acetylcholinesterase activity and its correlation with behavioral performances in 15-month old transgenic mice expressing the human C99 fragment of APP. J Neural Transm (Vienna) (2005) 0.79
Methyllycaconitine- and scopolamine-induced cognitive dysfunction: differential reversal effect by cognition-enhancing drugs. Pharmacol Res Perspect (2014) 0.79
Mouse chromosome 11 harbors genetic determinants of hippocampal strain-specific nicotinic receptor expression. Hippocampus (2008) 0.78
Modulation of spontaneous hippocampal synaptic events with 5-hydroxyindole, 4OH-GTS-21, and rAAV-mediated alpha7 nicotinic receptor gene transfer. Brain Res (2008) 0.77
Acetylcholine and antibodies against the acetylcholine receptor protect neurons and astrocytes against beta-amyloid toxicity. Int J Biochem Cell Biol (2013) 0.77
Astrocytic and microglial nicotinic acetylcholine receptors: an overlooked issue in Alzheimer's disease. J Neural Transm (Vienna) (2016) 0.76
High levels of mitochondrial DNA deletions in substantia nigra neurons in aging and Parkinson disease. Nat Genet (2006) 6.52
Heterogeneity of ubiquitin pathology in frontotemporal lobar degeneration: classification and relation to clinical phenotype. Acta Neuropathol (2006) 4.24
A harmonized classification system for FTLD-TDP pathology. Acta Neuropathol (2011) 4.15
Neuropathology of dementia in Parkinson's disease: a prospective, community-based study. Ann Neurol (2005) 3.31
Frontotemporal dementia in elderly individuals. Arch Neurol (2012) 2.21
Neuropathological substrates of psychiatric symptoms in prospectively studied patients with autopsy-confirmed dementia with lewy bodies. Am J Psychiatry (2004) 1.82
Adjust to target in type 2 diabetes: comparison of a simple algorithm with carbohydrate counting for adjustment of mealtime insulin glulisine. Diabetes Care (2008) 1.67
Why people see things that are not there: a novel Perception and Attention Deficit model for recurrent complex visual hallucinations. Behav Brain Sci (2005) 1.65
Towards defining the neuropathological substrates of vascular dementia. J Neurol Sci (2004) 1.63
Can a tool that automates insulin titration be a key to diabetes management? Diabetes Technol Ther (2012) 1.63
The impact of pathogenic mitochondrial DNA mutations on substantia nigra neurons. J Neurosci (2013) 1.59
Parkinson disease with dementia: comparing patients with and without Alzheimer pathology. Alzheimer Dis Assoc Disord (2009) 1.54
alpha-internexin is present in the pathological inclusions of neuronal intermediate filament inclusion disease. Am J Pathol (2004) 1.53
Dementia with Lewy bodies: a comparison of clinical diagnosis, FP-CIT single photon emission computed tomography imaging and autopsy. J Neurol Neurosurg Psychiatry (2007) 1.52
Case-fatality rate during a measles outbreak in eastern Niger in 2003. Clin Infect Dis (2005) 1.45
The rate of cognitive decline in Parkinson disease. Arch Neurol (2004) 1.44
alpha-Internexin aggregates are abundant in neuronal intermediate filament inclusion disease (NIFID) but rare in other neurodegenerative diseases. Acta Neuropathol (2004) 1.43
Quantification of myelin loss in frontal lobe white matter in vascular dementia, Alzheimer's disease, and dementia with Lewy bodies. Acta Neuropathol (2010) 1.31
Use of HRP-2-based rapid diagnostic test for Plasmodium falciparum malaria: assessing accuracy and cost-effectiveness in the villages of Dielmo and Ndiop, Senegal. Malar J (2010) 1.31
Burnout in medical students: a systematic review. Clin Teach (2013) 1.30
Estimating the burden of malaria in Senegal: Bayesian zero-inflated binomial geostatistical modeling of the MIS 2008 data. PLoS One (2012) 1.28
Patients with a novel neurofilamentopathy: dementia with neurofilament inclusions. Neurosci Lett (2003) 1.27
Identification of novel and improved antimitotic agents derived from noscapine. J Med Chem (2005) 1.20
Pathological correlates of frontotemporal lobar degeneration in the elderly. Acta Neuropathol (2010) 1.19
The most common type of FTLD-FUS (aFTLD-U) is associated with a distinct clinical form of frontotemporal dementia but is not related to mutations in the FUS gene. Acta Neuropathol (2011) 1.18
Cerebellar ataxia in patients with mitochondrial DNA disease: a molecular clinicopathological study. J Neuropathol Exp Neurol (2012) 1.17
Scale-up of home-based management of malaria based on rapid diagnostic tests and artemisinin-based combination therapy in a resource-poor country: results in Senegal. Malar J (2012) 1.13
Neuroleptic sensitivity in Parkinson's disease and parkinsonian dementias. J Clin Psychiatry (2005) 1.11
Ventilation-perfusion scintigraphy is more sensitive than multidetector CTPA in detecting chronic thromboembolic pulmonary disease as a treatable cause of pulmonary hypertension. J Nucl Med (2007) 1.05
Altered neurogenesis in Alzheimer's disease. J Psychosom Res (2006) 1.03
Sensory neuronopathy in patients harbouring recessive polymerase γ mutations. Brain (2011) 1.03
Neuropathological evidence for ischemia in the white matter of the dorsolateral prefrontal cortex in late-life depression. Int J Geriatr Psychiatry (2003) 1.02
Pathologies and pathological mechanisms for white matter hyperintensities in depression. Ann N Y Acad Sci (2002) 1.01
Expression analysis of dopaminergic neurons in Parkinson's disease and aging links transcriptional dysregulation of energy metabolism to cell death. Acta Neuropathol (2011) 1.01
Chronic nicotine treatment reduces beta-amyloidosis in the brain of a mouse model of Alzheimer's disease (APPsw). J Neurochem (2002) 0.99
Neurogenic abnormalities in Alzheimer's disease differ between stages of neurogenesis and are partly related to cholinergic pathology. Neurobiol Dis (2012) 0.98
A neuropathological study of periventricular white matter hyperintensities in major depression. J Affect Disord (2003) 0.97
Development of adult pluripotent stem cell therapies for ischemic injury and disease. Expert Opin Biol Ther (2007) 0.97
Dementia with Lewy bodies. Semin Clin Neuropsychiatry (2003) 0.94
The role of phytochemicals in the treatment and prevention of dementia. Drugs Aging (2011) 0.94
Evidence for ASD recurrence rates and reproductive stoppage from large UK ASD research family databases. Autism Res (2014) 0.91
Neuropathological correlates of volumetric MRI in autopsy-confirmed Lewy body dementia. Neurobiol Aging (2011) 0.91
Nicotine reduces A beta in the brain and cerebral vessels of APPsw mice. Eur J Neurosci (2004) 0.91
Sahel, savana, riverine and urban malaria in West Africa: Similar control policies with different outcomes. Acta Trop (2011) 0.91
Evaluation of Psn, HmuR and a modified LcrV protein delivered to mice by live attenuated Salmonella as a vaccine against bubonic and pneumonic Yersinia pestis challenge. Vaccine (2010) 0.91
Selective nicotinic receptor consequences in APP(SWE) transgenic mice. Mol Cell Neurosci (2002) 0.90
Development of a surrogate angiogenic potency assay for clinical-grade stem cell production. Cytotherapy (2012) 0.90
Aromatherapy in the management of psychiatric disorders: clinical and neuropharmacological perspectives. CNS Drugs (2006) 0.89
The quality of life of adults with attention deficit hyperactivity disorder: a systematic review. Innov Clin Neurosci (2012) 0.88
Mitochondrial DNA deletions cause the biochemical defect observed in Alzheimer's disease. Neurobiol Aging (2011) 0.87
Hallucinations predict attentional improvements with rivastigmine in dementia with lewy bodies. Dement Geriatr Cogn Disord (2004) 0.87
A double-blind placebo-controlled randomized trial of Melissa officinalis oil and donepezil for the treatment of agitation in Alzheimer's disease. Dement Geriatr Cogn Disord (2011) 0.86
Synaptic proteins and choline acetyltransferase loss in visual cortex in dementia with Lewy bodies. J Neuropathol Exp Neurol (2013) 0.86
Early-onset cataracts, spastic paraparesis, and ataxia caused by a novel mitochondrial tRNAGlu (MT-TE) gene mutation causing severe complex I deficiency: a clinical, molecular, and neuropathologic study. J Neuropathol Exp Neurol (2013) 0.86
A ruthenium (III) polyaminocarboxylate complex, a novel nitric oxide scavenger, enhances graft survival and decreases nitrosylated heme protein in models of acute and delayed cardiac transplant rejection. J Cardiovasc Pharmacol (2002) 0.86
Benefits of manual vacuum aspiration for abortion. Int J Gynaecol Obstet (2011) 0.85
Neuropathologically mixed Alzheimer's and Lewy body disease: burden of pathological protein aggregates differs between clinical phenotypes. Acta Neuropathol (2015) 0.85
Relationship between mitochondria and α-synuclein: a study of single substantia nigra neurons. Arch Neurol (2012) 0.85
Muscarinic receptors in basal ganglia in dementia with Lewy bodies, Parkinson's disease and Alzheimer's disease. J Chem Neuroanat (2003) 0.85
Dorsal motor nucleus of vagus protein aggregates in Lewy body disease with autonomic dysfunction. Brain Res (2009) 0.85
Inflammatory mediators in the frontal lobe of patients with mixed and vascular dementia. Dement Geriatr Cogn Disord (2008) 0.84
The effect of drug treatment on neurogenesis in Parkinson's disease. Mov Disord (2010) 0.84
Spiritual well-being in individuals with fibromyalgia syndrome: relationships with symptom pattern variability, uncertainty, and psychosocial adaptation. Res Theory Nurs Pract (2009) 0.84
Chronic ingestion of (3R,3'R,6'R)-lutein and (3R,3'R)-zeaxanthin in the female rhesus macaque. Invest Ophthalmol Vis Sci (2006) 0.84
An integrative review of the mental health of partners of veterans with combat-related posttraumatic stress disorder. J Am Psychiatr Nurses Assoc (2014) 0.83
Microangiopathy in the cerebellum of patients with mitochondrial DNA disease. Brain (2012) 0.83
Electronic signature, attestation, and authorship (updated). J AHIMA (2009) 0.83
Toxicity from a clonidine suspension. J Med Toxicol (2009) 0.82
Vitamin and mineral supplements: barriers and challenges for older adults. J Nutr Elder (2008) 0.82
Nicotinic acetylcholine receptor immunohistochemistry in Alzheimer's disease and dementia with Lewy bodies: differential neuronal and astroglial pathology. J Neurol Sci (2004) 0.82
Vaccines must be given in order to protect. J Infect Dis (2007) 0.81
Disturbances of consciousness in dementia with Lewy bodies associated with alteration in nicotinic receptor binding in the temporal cortex. Conscious Cogn (2002) 0.81
Increased binding to 5-HT1A and 5-HT2A receptors is associated with large vessel infarction and relative preservation of cognition. Brain (2009) 0.81
Loss of myelin-associated glycoprotein in kearns-sayre syndrome. Arch Neurol (2012) 0.81
Thalamic nicotinic receptors implicated in disturbed consciousness in dementia with Lewy bodies. Neurobiol Dis (2005) 0.81
Cholinesterase inhibitors may increase phosphorylated tau in Alzheimer's disease. J Neurol (2009) 0.81
Effect of co-administration of ketoconazole, a strong CYP3A inhibitor, on the pharmacokinetics, safety and tolerability of navitoclax, a first-in-class oral Bcl-2 family inhibitor, in cancer patients. Anticancer Res (2014) 0.81
Comparative distribution of binding of the muscarinic receptor ligands pirenzepine, AF-DX 384, (R,R)-I-QNB and (R,S)-I-QNB to human brain. J Chem Neuroanat (2002) 0.79
The distribution pattern of pathology and cholinergic deficits in amygdaloid complex in Alzheimer's disease and dementia with Lewy bodies. Acta Neuropathol (2006) 0.79
Partial loss of parvalbumin-containing hippocampal interneurons in dementia with Lewy bodies. Neuropathology (2011) 0.79
Proteasomal abnormalities in cortical Lewy body disease and the impact of proteasomal inhibition within cortical and cholinergic systems. J Neural Transm (Vienna) (2008) 0.79
Etiology of a suspected measles outbreak: preceding measles reduction activities in Pakistan. J Coll Physicians Surg Pak (2009) 0.79